Recent Headlines
Calvert Research Awarded Federal Grants Totaling Approximately $245,000 to Support Further Development of Its Age-Related Macular Degeneration Drug Candidate
Calvert Research, LLC announced today that one of the Company’s therapeutic development programs (T1-1081) qualified to receive federal grant funding totaling approximately $245,000 under the Patient Protection and Affordable Care Act of 2010 (“The ACT”), which will be used to... - November 17, 2010 - Calvert Research
Achieve Clinical Research Announces Influenza Research Studies in Birmingham, Alabama
Achieve Clinical Research, announces the launch of several research studies to test investigational treatment options for those already diagnosed with influenza. - November 14, 2010 - Achieve Clinical Research
NanoCor Therapeutics, Inc. is Awarded a Grant Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
NanoCor Therapeutics, Inc. (NanoCor) today announced the Company was awarded a grant under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP). The grant is being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care... - November 08, 2010 - NanoCor Therapeutics Inc.
Colorado’s Bioscience Industry Awarded Over $23 Million in Funding from Federal Qualifying Therapeutic Discovery Project Grant and Tax Credit Program
According to the Colorado BioScience Association (CBSA), Colorado’s bioscience industry received more than $23 million for 102 different projects in the Qualifying Therapeutic Discovery Project (QTDP) program, per data posted online Monday by the Internal Revenue Service (IRS), in conjunction with the Department of Health and Human Services (HHS). Colorado ranks in the top ten of states applying for credits and grants under the new program. - November 06, 2010 - Colorado BioScience Association
Clinical Trials of America, Inc., Participating in Pivotal Clinical Study of Novel Treatment for Type 1 Diabetes
Defend-2 Evaluating Drug Candidate, Otelixizumab, in New-Onset Type 1 Diabetes. - November 06, 2010 - Clinical Trials of America
Clinical Trials of America Names Pamela Pannier Clinical Operations Director
Pamela Pannier has joined Clinical Trials of America, Inc., as the company’s clinical operations director. Pannier will lead business development, including sourcing, managing and implementing new business opportunities in the Eugene and surrounding areas. “Pamela Pannier brings almost... - November 06, 2010 - Clinical Trials of America
Achieve Clinical Research Announces Osteoarthritis (OA) Research Studies in Birmingham, Alabama
Achieve Clinical Research, announces the launch of several research studies to test investigational treatment options for those already diagnosed with osteoarthritis (OA). - November 05, 2010 - Achieve Clinical Research
Patients Use More Specific Keywords While Seeking Clinical Trial Information Online, According to TrialX Research
A new research study finds that e-patients searching for health information related to clinical research studies tend to use longer and more specific keywords - November 04, 2010 - Applied Informatics
Revolutionary Vbeam® Perfecta Laser Treatment for Rosacea and Facial Veins
The Vbeam® Perfecta sets the gold standard in treatment of facial redness such as rosacea and facial veins. It is highly recommended for unsightly broken capillaries, spider hemangioms, telangectasia or skin discoloration on the face. - November 04, 2010 - Abrams Dermatology
Corengi Launches New Web Site to Help Type 2 Diabetes Patients Find Suitable Clinical Trials
www.corengi.com simplifies the clinical trial selection process; enables type 2 diabetes patients to learn which trials are right for them. - October 28, 2010 - Corengi, Inc.
The Colorado BioScience Association and 650+ Partners Oppose Amendments 60 and 61 & Proposition 101
The Colorado BioScience Association along with over 650 partners are opposed to three ballot measures facing Colorado this election – Amendment 60, Amendment 61 and Proposition 101. These three measures - also known as the 'ugly three' - are referred to as tax breaks, but will have a devastating impact on Colorado and the companies located in the state for years to come. - October 27, 2010 - Colorado BioScience Association
Stemedica International Announces Joint Venture with AnC Bio Group to Manufacture Allogeneic Adult Stem Cells
Stemedica International, S.A., a wholly owned subsidiary of Stemedica Cell Technologies, Inc., announced the signing of an agreement to form a joint venture with AnC Bio, a global manufacturer of stem cell-based products. The new venture, StemedicaAnC, will manufacture allogeneic adult stem cells developed by Stemedica for the treatment of ischemic stroke and other degenerative disorders. - October 24, 2010 - Stemedica Cell Techechnologies
Clinical Trials of America Announces Don Dickerson as President
Donald Dickerson, experienced business leader and clinical studies manager, joins Clinical Trials of America as the company’s new president. Dickerson, who has developed and advanced profitable companies and divisions in global health, technology, and financial service, now manages all... - October 22, 2010 - Clinical Trials of America
Colorado BioScience Association and Two of the State’s Economic Development Entities, Tout Colorado’s Strengths at AdvaMed 2010
Representatives from the Colorado BioScience Association, Colorado Office of Economic Development and International Trade and Metro Denver Economic Development Corporation will showcase Colorado’s medical device and diagnostics sectors during the 2010 AdvaMed: The MedTech Conference in Washington D.C., October 18-20. - October 20, 2010 - Colorado BioScience Association
Clinical Trials of America’s CEO & Chief Medical Officer Presents at MAGI’s Clinical Research Conference – 2010 West
Dr. Richard Beyerlein explains how to be a clinical researcher’s “sponsor of choice.” - October 16, 2010 - Clinical Trials of America
Stemedica Announces Completion of Clinical Allogeneic Adult Stem Cell Master Bank
A world leader in allogeneic adult stem cell manufacturing and research, Stemedica Cell Technologies, Inc. announced the completion of its proprietary master bank of mesenchymal bone marrow-derived stem cells. - October 15, 2010 - Stemedica Cell Techechnologies
Achieve Clinical Research Announces Rheumatoid Arthritis Research Studies in Birmingham, Alabama
Achieve Clinical Research, announces the launch of several research studies to test investigational treatment options for those already diagnosed with rheumatoid arthritis. - October 14, 2010 - Achieve Clinical Research
Creativ-Ceutical to be Centre Stage at ISPOR Europe 2010
Strengthening its positioning as one of the major pan-European consulting companies in pricing, market access and health economics, Creativ-Ceutical will be present in force at ISPOR 2010 from 6-9 November in Prague. - October 13, 2010 - Creativ-Ceutical
Optasia Medical to Demonstrate Innovative X-Ray Analysis Capabilities at Leading Industry Events
Optasia Medical introduces powerful new clinical workflow tools for the interpretation of x-rays for osteoporosis and arthritis - October 12, 2010 - Optasia Medical, Ltd.
Colorado BioScience Association Announces Winners of Its 2010 Awards, Honoring The Best of Colorado's Bioscience Industry
The Colorado BioScience Association (CBSA) honored the outstanding bioscience companies and individuals in the state during its 2010 Annual Awards Dinner held in conjunction with the BioWest Conference & Expo at the Denver Grand Hyatt. The Annual Awards Dinner gives CBSA the ability to showcase companies and individuals that have had an outstanding year and to celebrate the industry as a whole. - October 11, 2010 - Colorado BioScience Association
IonSense Expands Product Line with ASAP Open-Air Ionization Source
IonSense to sell Atmospheric Solids Analysis Probe (ASAP) as Entry Level Source for Open-Air Mass Spectrometry - October 08, 2010 - IonSense, Inc.
Adaptive Site Monitoring Improves Clinical Research Efficiency: DIA Invites Health Decisions to Discuss
Health Decisions CEO Dr. Michael Rosenberg will explore the implications of advanced e-monitoring models during two sessions at the DIA 4th Annual Clinical Forum. - October 08, 2010 - Health Decisions
New to the Medik8 Beta Range – The Anti-Acne Kit
The Medik8 “beta” range is constantly evolving, with 2010 proving to be a pivotal year in the maturing of this award-winning line for problem skin. September 2010 sees the launch of the brand new Anti-Acne Kit. Combining state of the art formulations with on the pulse market focus, Medik8 have designed two unique products to create a convenient dual treatment pack. - October 06, 2010 - Pangaea Ltd.
Introducing Professional PDT from Medik8
Light Amplifier™ RX has been formulated by Medik8 scientists to boost the clinically proven results from increasingly popular light therapy. This novel and unique lightweight 20% strength serum is applied prior to light therapy procedures in-clinic and dramatically increases efficacy of all light-based hardware regardless of manufacturer; a retail version is also available for at-home use with a personal light therapy lamp. - October 06, 2010 - Pangaea Ltd.
Is Medik8® Now Chasing Men with Its Oil-Free Antioxidant Blue Aox™?
Medik8 Skin Research has developed Blue AOX™; a powerful antioxidant serum to put skin aging on hold. - October 06, 2010 - Pangaea Ltd.
Innovative Technology for Skin Rejuvenation Therapy-Medik8 Launches Titanium Dermastamp
Medik8 Skin Research is launching a clever, new skin needling device to expand its current skin needling range. - October 05, 2010 - Pangaea Ltd.
Health Decisions CEO to Address Adaptive Patient Enrollment at Achieving Operational Efficiency in Clinical Trials 2010
Dr. Michael Rosenberg will discuss how continuously adapting enrollment during studies prevents delays and setbacks. - October 03, 2010 - Health Decisions
BJS Biotechnologies Launches UF1 at Biotechnica
Ultra-rapid next-generation thermal cycler could bring PCR to point-of-care - October 03, 2010 - BJS Biotechnologies Ltd
Sharklet Technologies Wins Dorsey & Whitney Venture Showcase Award, Presented at 2010 BioWest Conference & Expo
Sharklet Technologies, Inc., has won the Dorsey & Whitney Venture Showcase Award at the 2010 BioWest Conference & Expo in Denver. The announcement is made by Holli Baumunk, President & CEO of the Colorado BioScience Association (CBSA), who says the $7,500 Venture Showcase award was provided by the Dorsey & Whitney law firm and announced at the 2010 CBSA Awards Dinner. - October 02, 2010 - Colorado BioScience Association
OSO BioPharmaceuticals Appoints Susan Schniepp VP of Quality
OSO BioPharmaceuticals Manufacturing, LLC, has named Susan Schniepp as vice president of quality. In managing all operational quality-related issues, Schniepp is responsible for cGMP compliance of OsoBio’s facility. Quality-related matters concerning validation as well as regulatory affairs,... - September 30, 2010 - OSO BioPharmaceuticals Manufacturing, LLC
Mercodia Will Market Their Oxidized LDL ELISA as an In-vitro Diagnostic for Clinical Use
The United States Food and Drug Administration (FDA) has determined that the Mercodia Oxidized LDL ELISA can be used clinically as an IVD. Oxidized LDL has been shown to play a key role in the initiation and progression of atherosclerosis, making the Mercodia Oxidized LDL ELISA a critical biomarker in cardiovascular disease-related studies and the most widely used method commercially available today. - September 27, 2010 - Mercodia Inc.
DNA Diagnostics Centre (DDC) Opens Their 4,000th Worldwide DNA Testing Sample Collection Centre
DDC testing laboratory expands its worldwide network by adding new DNA sample collection facilities. - September 27, 2010 - DNA Diagnostics Centre
Heart Test Laboratories MyoVista™ System Awarded European CE Mark for Heart Disease Screening
Heart Test Laboratories, Inc. today announced that the MyoVista™, its medical screening system which detects Myocardial abnormalities, has been awarded the CE Mark certification by TÜV SÜD. The CE mark (Conformité Européenne) is a mandatory European marking for certain product groups to indicate conformity with essential health and safety requirements. - September 25, 2010 - Heart Test Labs
Noesys Data Launches a New Data Service to Identify and Classify Arrhythmias in Safety Pharmacology Studies at 10th Annual Safety Pharmacology Society Meeting
During the annual meeting of the Safety Pharmacology Society in Boston Noesys Data unveiled a service that reviews cardiac safety study data for the occurrence of arrhythmia. A panel of Board Certified veterinary cardiologists to provide expert review and customer reports. - September 24, 2010 - Noesys Data
2010 BioWest Conference & Expo to Showcase 40+ New Technologies, Products and Services
More than 40 exhibitors will be showcasing new technology, products and services for 500+ attendees at the 2010 BioWest Conference & Expo, September 29 and 30, at the Grand Hyatt Denver, 1750 Welton. BioWest, in its eighth year, is the Rocky Mountain region’s preferred venue for visiting and learning about the bioscience industry. - September 23, 2010 - Colorado BioScience Association
IonSense to Present Rapid Screening Solutions for Food Safety at the AOAC Annual Meeting and Exposition
DART MS Analyzes Targeted and Non-Targeted Contaminants in Seconds. - September 21, 2010 - IonSense, Inc.
Proactive Medical Management Assists with Proposed OSHA Regulation Changes
JFK Medport and Insight Diagnostics, Inc. (IDI) have formed a strategic alliance that provides state of the art technology for the diagnosis and treatment of soft tissue injuries, enhancement of employee productivity and assisting employers with new Occupational Safety and Health Administration... - September 15, 2010 - Insight Diagnostics Inc
Four Finalists Selected for BioWest 2010 Venture Showcase Competition, Presenting Life-Changing Technologies
Cutting-edge development of a universal influenza vaccine, creation of an innovative hybridCpeptide manufacturing process, groundbreaking wastewater treatment through a new algae production system, and a revolutionary nontoxic surface treatment to control the growth of bacteria in hospitals, comprise the four finalists in this year’s BioWest Venture Showcase competition. - September 13, 2010 - Colorado BioScience Association
Colorado's Emmy® Award Winning Heroine Dr. Temple Grandin Keynotes CBSA Awards Dinner at 2010 BioWest Conference & Expo
General registration is now open for the Rocky Mountain Region’s Premier Bioscience Conference & Expo, BioWest 2010. More than 700 participants are expected at this year’s event, September 29-30, at the Grand Hyatt (1750 Welton) in Denver. Headlining the Annual Awards Dinner during the 2010 BioWest Conference is Dr. Temple Grandin, noted author, speaker, scientist and autism expert who leads an impressive line up of national and international industry speakers and panelists. - September 07, 2010 - Colorado BioScience Association
New Hope Fertility Centre Launches Frozen Egg Banking: The Next Logical Step in IVF
In Vitro Fertilization is a technology on the cutting edge of medical science. It was a science that was created to meet a basic human need, to bring the gift of childbirth to parents who were biologically unable to conceive on their own. - September 04, 2010 - New Hope Fertility Center
National Institutes of Health Award a $1.7M SBIR Grant to MicroTransponder to Develop a Neurostimulation-Based Therapy to Treat Tinnitus
MicroTransponder, Inc., a privately-held medical device company, announced that it has been awarded a $1.7M SBIR grant from the National Institute on Deafness and Other Communication Disorders (NIDCD) to develop a neurostimulation-based therapy for the treatment of Tinnitus. This project builds... - September 01, 2010 - MicroTransponder Inc.
C.R. England and Insight Diagnostics, Inc. Announce Successful Collaboration Enhances Employee Productivity
C.R. England and Insight Diagnostics, Inc. (IDI) have formed a strategic alliance to provide state of the art technology to enhance patient care at England’s Lakeside Clinic. IDI’s FDA approved Electrodiagnostic Functional Assessment (EFA) is a Class II diagnostic device and service protocol for assessing soft tissue injuries. - August 27, 2010 - Insight Diagnostics Inc
New England Fertility Institute of Stamford Connecticut to Attend London Fertility Show November 5th and 6th
The New England Fertility Institute and Dr. Gad Lavy Medical Director will be attending and exhibiting at the London Fertility Show in the Olympia Convention Center November 5th and 6th 2010. Dr. Lavy will be doing complimentary consultations for individuals and couples interested in egg donation and gestational surrogacy in the United States. - August 27, 2010 - New England Fertility Institute
CW Optics Announces Clinical Trial of Breakthrough Technology for Wound Imaging for Diabetics
CW Optics, Inc. announced today a clinical trial at Richmond's Chippenham and Johnston-Willis (CJW) Medical Center to investigate the safety and efficacy of WoundImager®, an advanced optical imaging device for monitoring the effectiveness of therapeutic management of chronic wounds caused by... - August 27, 2010 - CW Optics, Inc.
CW Optics Announces Clinical Trial of Breakthrough Technology for the Detection of Intravenous Infiltration
CW Optics, Inc. announced today the launch of a clinical trial at the Virginia Commonwealth University Health System to investigate the safety and efficacy of ivWatch®, a novel optical device for monitoring intravenous (IV) infusion sites for infiltration. Each year, there are approximately 150... - August 27, 2010 - CW Optics, Inc.
Bio-Med QC Offers an Indiana Pharmacy Exclusive
Bio-Med QC has recently designed the most comprehensive and the most effective CSP quality assurance microbiology system available. The Bio-Shield AT system includes added value, on site training and saves you money over the alternative options that provide no microbiology support. Bio-Med QC has... - August 26, 2010 - Bio-Med QC
New Hope Fertility Center Offers Unique Blastocyst Guarantee
New Hope Fertility Center, a leader in Egg Donation, now offers a unique guarantee designed to dramatically increase successful implantation rates and embryo viability. - August 20, 2010 - New Hope Fertility Center
DDC Launches UK Mobile DNA Sample Collection Service
DNA Diagnostics Centre has launched a new service enabling private clients, immigration law specialists, family and child law solicitors to have DNA samples collected by a mobile DNA collection team throughout the United Kingdom. - August 18, 2010 - DNA Diagnostics Centre
CEO Will Rosellini and MicroTransponder Inc. Named Finalists for the 10th Annual Tech Titans Awards
The MTBC has named CEO Will Rosellini a finalist for the Tech Innovator category and MicroTransponder a finalist for the Emerging Company Horizon category for the 10th Annual Tech Titan Awards in Texas. - August 17, 2010 - MicroTransponder Inc.
Clinical Trials in Russia. 2nd Quarter 2010.
The Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (alias RosZdravNadzor, RZN) approved 178 new clinical trials of all types including local and bioequivalence studies during the second quarter of 2010 demonstrating a 38% increase over the corresponding period of last year. - August 14, 2010 - Synergy Research Group